⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IBRX News
ImmunityBio, Inc. Common Stock
IBRX INVESTOR NOTICE: ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
globenewswire.com
IBRX
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
globenewswire.com
IBRX
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 Ready to Announce with Confidence?
newsfilecorp.com
IBRX
Form 8-K
sec.gov
INKT
IBRX
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
globenewswire.com
INKT
IBRX
IBRX Stockholders Have Opportunity to Lead ImmunityBio, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
accessnewswire.com
IBRX
Pomerantz LLP Shares Class Action Details With Investors in ImmunityBio, Inc. – IBRX
accessnewswire.com
IBRX
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
accessnewswire.com
IBRX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX
prnewswire.com
IBRX
IBRX DEADLINE NOTICE: ImmunityBio, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 26, 2026
accessnewswire.com
IBRX